Study Administers IMG-7289 to First Patients with MF

The first patients have been dosed in a Phase 1/2 clinical trial of IMG-7289 for the treatment of myelofibrosis (MF), according to Imago BioSciences.

The clinical-stage pharmaceutical company is developing novel therapies for hematological and inflammatory diseases. Myelofibrosis is characterized by the production of inflammatory cytokines, and IMG-7289 is an investigational lysine-specific demethylase 1 (LSD1) inhibitor intended to suppress that production.

Read more

Posted in Uncategorized.

Leave a Reply

Your email address will not be published. Required fields are marked *